ClinicalTrials.Veeva

Menu
C

Chandler Clinical Trials | Chandler, AZ

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

ESK-001
Lorundrostat
AD109
KarXT
Aroxybutynin
Seltorexant
Atomoxetine
JNJ-89495120

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

11 of 14 total trials
Locations recently updated

A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events (TRANSFORM)

TRANSFORM is a prospective, randomized, open blinded endpoint (PROBE), event-driven, pragmatic trial in patients who are at increased risk for athero...

Enrolling
Diabetes Mellitus, Type 2
Metabolic Syndrome
Device: The Cleerly CAD Staging System

The goal of this clinical trial is to learn if ESK-001 works to treat moderate to severe plaque psoriasis. The main questions it aims to answer are:*...

Enrolling
Plaque Psoriasis
Drug: ESK-001
Drug: Placebo

The purpose of this study is to evaluate the safety and efficacy of KarXT in adult participants with mild to severe Alzheimer's Disease (AD) with mod...

Enrolling
Alzheimer Disease
Drug: Placebo
Drug: KarXT

The main purpose of this study is to evaluate the efficacy of mRNA 1647 vaccine in CMV-seronegative female participants and to evaluate the safety an...

Active, not recruiting
Cytomegalovirus Infection
Biological: mRNA-1647
Biological: Placebo

The purpose of this study is to evaluate how well JNJ-89495120 works (anti-depressant effects) and how well it is tolerated as compared to placebo on...

Enrolling
Depressive Disorder, Major
Drug: JNJ-89495120
Drug: Placebo
Locations recently updated

The combination drug composed of aroxybutynin and atomoxetine, designated AD109, is being developed by Apnimed for the treatment of obstructive sleep...

Invitation-only
OSA
Drug: Aroxybutynin and Atomoxetine
Locations recently updated

The objective of the ESK-001-018 long term extension is to evaluate the safety and efficacy of ESK-001 over time. The scientific questions it aims to...

Enrolling
Psoriasis
Severe Psoriasis
Drug: Open-Label ESK-001
Drug: Blinded ESK-001

This study is to evaluate the long-term safety, efficacy and tolerability of lorundrostat (an aldosterone synthase inhibitor) in subjects with hypert...

Active, not recruiting
Hypertension
Drug: lorundrostat
Drug: Placebo

This is a Phase 3 Randomized Double-Blind Placebo-Controlled 1-year Parallel-Arm Study to Compare a Fixed Dose Combination of AD109 to Placebo in Obs...

Active, not recruiting
OSA
Drug: AD109
Drug: Placebo

The purpose of this study is to know how well seltorexant works, and also to evaluate safety and maintenance effect of seltorexant compared with plac...

Enrolling
Depressive Disorder, Major
Drug: Selective Serotonin Reuptake Inhibitor (SSRI)/Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
Drug: Placebo

This study evaluates the efficacy and safety of benralizumab as an add-on therapy in uncontrolled eosinophilic asthma participants treated with mediu...

Enrolling
Eosinophilic Asthma
Combination Product: Placebo for Benralizumab
Combination Product: benralizumab

Trial sponsors

Moderna logo
A
Apnimed logo
Janssen (J&J Innovative Medicine) logo
M
AstraZeneca logo
C
Karuna Therapeutics logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems